GSK expands Asia-Pacific reach for Trelegy Ellipta
Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US. Image Credit: MAXSHOT.PL / Shutterstock. Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include its use as a maintenance therapy for adults with asthma. The Singapore agency also approved a new … GSK expands Asia-Pacific reach for Trelegy Ellipta weiterlesen
Füge diese URL in deine WordPress-Website ein, um den Inhalt einzubetten
Füge diesen Code in deine Website ein, um den Inhalt einzubetten